PharmaFocus Today – Page 20 – media

ADB116 for injection receives approval for clinical trial

October 24, Aidi Pharmaceuticals(688488.SH) announced that the company and its controlling subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., have received the “Notice of Approval for Clinical Trial of a Drug” from the National Medical Products Administration (NMPA), authorizing the company to conduct clinical trials of its investigational Class 2 chemically modified new drug, ADB116 for injection. This drug is intended for thrombolytic therapy in patients with acute ischemic stroke. If successfully approved for marketing in the future, it will provide more treatment options for stroke patients and further enhance the company’s core competitiveness and development potential. However, it should be noted that after receiving the Notice of Approval for Clinical Trial of a Drug, the drug must undergo clinical trials to obtain efficacy and safety data, and must undergo review and approval by the NMPA before it can be manufactured and marketed. Source：https://finance.eastmoney.com/a/202510243543623696.html
- Source: drugdu
- 103
- October 27, 2025
Selling subsidiary equity to Hillhouse Capital to fully focus on CRDMO

On October 26, WuXi AppTec (603259/02359) issued an announcement that its wholly-owned subsidiary Shanghai WuXi AppTec New Drug Development Co., Ltd. intends to transfer its 100% equity in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. to Shanghai Shiherong Enterprise Management Consulting Co., Ltd. and Shanghai Shihemu Enterprise Management Consulting Co., Ltd. for a consideration of RMB 2.8 billion. To focus on the CRDMO (Contract Research, Development and Manufacturing) business model, focusing on drug discovery, laboratory testing, process development and manufacturing services, and accelerating the deployment of global capabilities and production capacity, the company’s wholly-owned subsidiary Shanghai WuXi intends to transfer 100% of its equity in Kangde Hongyi and Jinshi Pharmaceutical.To the transferees. The transferees are all newly established companies by Hillhouse Capital through its private equity funds for the purpose of this transaction. In the first three quarters of 2025, WuXi AppTec achieved revenue of 32.857 billion yuan ...
- Source: drugdu
- 160
- October 27, 2025
First patient enrolled in Phase IIa clinical trial of ophthalmology drug for delaying myopia in children in China

On October 26, Yuanda Pharmaceutical announced that the first patient has been enrolled in a Phase IIa clinical study in China of its innovative ophthalmic drug, GPN00884, for slowing the progression of myopia in children. This marks the beginning of a crucial phase of dosing and preliminary efficacy assessment for GPN00884. This Phase IIa trial is a randomized, double-blind, placebo-controlled study enrolling over 80 myopic subjects aged 6 to 12 years. The study aims to preliminarily evaluate the efficacy and safety of GPN00884 eye drops in slowing the progression of myopia in children. Source：https://finance.eastmoney.com/a/202510263544490960.html
- Source: drugdu
- 122
- October 27, 2025
Novartis to acquire Avidity Biosciences for approximately $12 billion

Novartis agreed to acquire Avidity Biosciences for approximately $12 billion, or $72 per share. The acquisition will help Novartis expand its rare disease treatment pipeline, particularly for muscle diseases. Avidity Biosciences will spin out its early-stage heart disease treatment program into a new company called Spinco, which is expected to go public. Avidity Biosciences, whose flagship drug Del-zota is in early-to-mid-stage clinical trials for Duchenne muscular dystrophy, also has other drug candidates for severe muscle diseases. The acquisition fits with Novartis’ recent strategy of addressing patent cliffs on some of its blockbuster drugs through a series of deals. Source：https://finance.eastmoney.com/a/202510273544630680.html
- Source: drugdu
- 76
- October 27, 2025
TSL2109 capsules approved for clinical trials

recently announced that its wholly-owned subsidiary, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., received the “Notice of Approval for Clinical Trial of Drugs” from the National Medical Products Administration (NMPA) for TSL2109 Capsules for the treatment of advanced solid tumors. TSL2109 Capsules, jointly developed by Jiangsu Diyi and China Pharmaceutical University, is a novel dual-target small molecule inhibitor. It selectively inhibits the downstream signaling pathways of both targets, arrests the tumor cell cycle, and induces apoptosis, achieving a synergistic killing effect. Currently, no similar dual-target drugs have entered clinical trials outside of China . As a traditional pharmaceutical company specializing in traditional Chinese medicine and chemical drugs, Tasly has been actively transforming its focus into innovative drugs in recent years. TSL2109 Capsule is a dual-target small molecule inhibitor with a novel structure, a first of its kind globally. However, investors should be aware of the high risks of drug development. Source: https://wap.eastmoney.com/a/202509243522600041.html
- Source: drugdu
- 166
- October 26, 2025
Salubris’s clinical trial application for SAL0137 has been accepted

On the evening of October 15, Xinlitai(002294) issued an announcement stating that the company received an acceptance notice approved and issued by the National Medical Products Administration, and the clinical trial application of the company’s independently developed innovative small molecule drug SAL0137 tablets (project code: SAL0137) was accepted. Xinlitai said that SAL0137 is a product developed by the company with independent intellectual property rights.The company’s application for SAL0137, an oral small molecule drug, is for clinical trials for the treatment of elevated lipoprotein (a). https://finance.eastmoney.com/a/202510153535045923.html
- Source: drugdu
- 132
- October 26, 2025
Sugemalimab receives positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use

On the morning of October 17, CStone Pharmaceuticals announced on the Hong Kong Stock Exchange that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, recommending the approval of sugemalimab monotherapy for the treatment of adult patients with unresectable stage III non-small cell lung cancer (NSCLC) whose tumor cells express PD-L1 ≥1%, have no epidermal growth factor receptor (EGFR)-sensitive mutations or ALK or ROS1 genomic alterations, and have not progressed after platinum-containing chemoradiotherapy (CRT). https://finance.eastmoney.com/a/202510173536614458.html
- Source: drugdu
- 85
- October 18, 2025
Buchang Pharmaceutical’s subsidiary partners with WuXi AppTec to expand preclinical drug research with a contract exceeding 10 million yuan

On October 16, Buchang Pharmaceutical(603858) announced that its controlling subsidiary Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. and Suzhou WuXi AppTecNew Drug Development Co., Ltd. signed a “Technical Service Contract” with Luzhou Buchang Pharmaceutical Co., Ltd. The total contract amount is RMB 10.8 million, including 6% tax. Luzhou Buchang will pay the relevant fees in installments as agreed in the contract. The collaboration aims to entrust WuXi AppTec to conduct pharmacokinetic and toxicology testing projects, which is expected to help expand the company’s drug research and development capabilities and scope, and save clinical trial time and costs. As of December 31, 2024, Luzhou Buchang’s total assets were 2.223 billion yuan, total liabilities were 2 billion yuan, and net assets were 223 million yuan. In 2024, it achieved operating income of 47,100 yuan and a net profit of -16.24 million yuan. By June 30, 2025, total assets will rise to 2.34 billion ...
- Source: drugdu
- 76
- October 18, 2025
MRX-5 has completed Phase I clinical trials in healthy subjects in Australia

The latest investor relations activity record released by MicuRx Pharmaceutical on October 15 shows that the company participated in the analyst meetings of Huashang Fund and Jianxin Pension on October 13, and exchanged views with all parties on the research and development prospects and progress of the company’s products. Regarding the clinical application prospects of MRX-4 after it is launched on the market, the company stated that MRX-4 is a water-soluble prodrug of contezolizumab tablets, which is converted into contezolizumab in the body to exert therapeutic effects. The injectable dosage form has greatly expanded the usage scenarios. According to the “Guiding Principles for the Clinical Application of Antimicrobial Drugs” issued by the National Health Commission in 2015, intravenous administration can quickly reach high drug concentrations. For patients with severe infections and rapid disease progression who require emergency treatment, intravenous administration should be the first choice for clinical use of antibiotics. ...
- Source: drugdu
- 91
- October 18, 2025
Why Might GLP-1 Drugs Reduce Alcohol Cravings? New Experiment Suggests An Answer

By Dennis Thompson HealthDay ReporterTHURSDAY, Oct. 16, 2025 (HealthDay News) — Weight-loss drugs like Ozempic and Zepbound appear to reduce alcohol cravings, but doctors have been at a loss to explain why – until now. Glucagon-like peptide-1 (GLP-1) drugs appear to slow the speed at which alcohol enters the bloodstream, which also diminishes its effects on a person’s brain, according to pilot study results published Oct. 15 in the journal Scientific Reports. Essentially, people don’t feel the effects of alcohol as intensely if they’re taking a GLP-1 med, researchers said. “People who drink know there’s a difference between nursing a glass of wine and downing a shot of whiskey,” researcher Alex DiFeliceantonio said in a news release. She’s interim co-director of the Roanoke, Virginia-based Fralin Biomedical Research Institute at VTC’s Center for Health Behaviors Research. Both drinks contain the same amount of alcohol, but the shot brings a rapid increase ...
- Source: drugdu
- 86
- October 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.